Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

Bruno Vellas(Centre Hospitalier Universitaire de Toulouse), Cristina Sampaio(Dorothea Haus Ross Foundation), Gordon Wilcock(University of Oxford), H. Robert Brashear(Brigham and Women's Hospital), Suzanne Hendrix(TetraLogic Pharmaceuticals (United States)), Michael Grundman(University of San Diego), Nick C. Fox(NIHR Queen Square Dementia Biomedical Research Unit), Philip Scheltens(Amsterdam University Medical Centers), María C. Carrillo(Brigham and Women's Hospital), Paul Aisen(University of California, San Diego), Harald Hampel(Sorbonne Université), Jesse M. Cedarbaum(Butler Hospital), Karl Broich(Federal Institute for Drugs and Medical Devices), Lon S. Schneider(University of Southern California), Rachelle S. Doody(Baylor College of Medicine), Eric Siemers(Eli Lilly (United States)), Zaven S. Khachaturian(University of Southern California), Michael W. Weiner(University of California, San Francisco), Ezio Giacobini(University of Geneva), Sandrine Andrieu(Université Toulouse III - Paul Sabatier), Jacques Touchon(Inserm), Reisa A. Sperling(Harvard University), Bruno Dubois(Portland State University)
Alzheimer s & Dementia
June 26, 2013
Cited by 145


Related Papers